MarketBeat
23 Sept 2026, 04:02 UTC · 7w ago
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
Impact · against what's priced in
The update is largely neutral as the market has already priced in a significant deceleration for Neurocrine and is discounting the impact of new product launches. While the CRENESSITY run rate of $750 million is strong, the stock's current valuation rejects the idea that these new assets can meaningfully offset the impending 2029 Medicare price cliff for INGREZZA.
- NBIX+0.20
Challenges what's priced in
- The price assumes





